Brain Cancer Clinical Trials in Massachusetts

Showing 101-120 of 154 trials

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

NCT01260506

The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.

Glioblastoma Multiforme

Vascular Biogenics Ltd. operating as VBL Therapeutics75 participantsStarted Dec 2010

Boston, Massachusetts, United States • Durham, North Carolina, United States • San Antonio, Texas, United States +1 more locations

COMPLETEDPhase 226 miles

ANG1005 in Patients With Recurrent High-Grade Glioma

NCT01967810

This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.

GliomaGlioblastomaBrain Tumor, Recurrent

Angiochem Inc73 participantsStarted Oct 2013

La Jolla, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +9 more locations

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

ANG1005 in Patients With Recurrent High-Grade Glioma

Brain Cancer Trials in Other Cities

Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas

First in Patient Study for PF-06840003 in Malignant Gliomas

Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

Tivozanib for Recurrent Glioblastoma

Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Advanced MRI Applications Development

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

MET-PET for Newly Diagnosed Glioblastoma

Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Radiation Therapy in Treating Young Patients With Gliomas

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Multi-site Validation and Application of a Consensus DSC-MRI Protocol

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Other Conditions in Massachusetts